Immune-Mediated Thrombocytopenia in Dogs: Welfare Management

Immune-mediated thrombocytopenia is an autoimmune condition causing platelet destruction in dogs, with welfare risks from severe bleeding and immunosuppressive treatment.

Key Facts

IMT causes the immune system to destroy circulating platelets, leading to platelet counts below 30,000 per microlitre in severe cases
Clinical signs include petechiae, ecchymoses, mucosal bleeding, and in severe cases, life-threatening haemorrhage
Cocker Spaniels, Poodles and Miniature Schnauzers have breed predispositions
High-dose corticosteroid therapy achieves remission in most cases — second-line agents (vincristine, azathioprine) are used for refractory disease

Welfare Considerations

IMT welfare management is a two-sided challenge: the uncontrolled disease causes life-threatening haemorrhage, while the immunosuppressive treatment required for control carries significant welfare costs including gastrointestinal ulceration, increased infection risk and behavioural changes from corticosteroid excess. The welfare priority is achieving remission promptly with an appropriate dose, then tapering to the minimum effective maintenance level as rapidly as safely possible. Response monitoring using platelet counts guides dose reduction to limit cumulative steroid welfare impacts.

What You Can Do

Restrict exercise during acute thrombocytopenia to prevent trauma-induced haemorrhage at very low platelet counts
Begin high-dose corticosteroid therapy promptly after diagnosis — early treatment reduces haemorrhage welfare risk
Taper steroid dose as platelet counts recover — the minimum effective dose reduces iatrogenic welfare costs substantially
Monitor for treatment-related gastrointestinal signs and consider gastric protectants during high-dose corticosteroid phases